CLINICAL HANDBOOK OF SCHIZOPHRENIA

Index 641Lifestyle factors, 21comorbidity and, 425–426in hypertension, 429–430, 430tLinkage analysis, 58–59gene identification and, 59–60results of, 62Lipid abnormalities, clozapinerelated,183–184Lipid disorders, co-occurring,132Listening, value of, 571Lithium, 187in PACE model, 388Liverpool University Side EffectRating Scale, 402Lobotomy, 298Lorazepam, for catatonia, 190Loxapine (Loxitane), dosing of,163tLoxitane. See Loxapine(Loxitane)LSDclinical experiments with, 626studies of, 7Lurasidone, 32Lysergic acid diethylamide. SeeLSDMagnetic resonance imaging, 9,36–37functional, 9–10, 39–40Magnetic resonance spectroscopy,37Magnetoencephalography, 40–41Major depressive disorder, ECTindicated for, 197Malnutrition, 19Managed care, 514Manchester Short Assessment ofQuality of Life Scale, 584,584tManic core syndrome, 108Manic depressive insanity, 4Mannheim–World HealthOrganization study, 107Marital status, 21–22MATRICS, 193Measurement and TreatmentResearch to ImproveCognition in Schizophrenia,96–97, 193Med-eMonitor, 211–212, 211fMedia, mental illness stigma and,536–537Medicaid, 513Medical comorbiditycommon conditions, 427–434description, 424–427impact, 425key points, 434lifestyle factors and, 425–426potential barriers to treatment,426–427, 426tprevalence, 424–425quality of services, 425–426See also Co-occurring disordersMedical conditionsamong homeless people withschizophrenia, 413–414versus schizophrenia, 123Medical Outcome Study, 585Medicare, 513Medication adherencewith first-episode psychosis,371improving, 271suicide risk and, 500treatment of, 149t, 150–151Medication management,evidence-based, 542Medications, 79in ACT, 331algorithms for, 150t“antisuicidal,” 499–500assessment of, 313in cognitive rehabilitation, 256CYP450–inhibiting, 166dosing of, smoking and, 166in ER management, 341for hypertension, 430for inmates with schizophrenia,361in inpatient treatment, 344treatment plans for, 148–149,150tSee also Antipsychotics;Pharmacotherapy; specificagentsMEG. SeeMagnetoencephalographyMellaril. See Thioridazine(Mellaril)Memory, episodic, 93Mental health, religion/spirituality and, 593Mental health agenciescase managers’ role in, 310–311, 311tspiritual/religious discussiongroups and, 602Mental health carefinancing of, 513–514recovery revolution in, 570–572spending for, 508–510Mental health courts, 303Mental health interventions,evidence-based, 542–543Mental health services, changesin, 298–299, 543Mental illnesscriminalization of persons with,355cultural attitudes toward, 550–551disclosing, 539parenting programs and, 478self-help groups for, 299–300stigma of, 533–540. See alsoStigmaMental illness label, 533Mental Patients’ LiberationProject, 301Mental retardationDSM-IV-TR criteria for, 438prevalence of comorbidpsychiatric disorders, 439See also Intellectual disabilityMental status, assessment of, 313Mentally ill chemically addictedpersons, homelessness and,416Mesocortical dopamine pathway,28, 33Mesolimbic dopamine pathway,28, 33Metabolic conditions, cooccurring,130–132Metabolic syndromeatypical antipsychotics and,433–434co-occurring, 131–132Metacognition, targeting incognitive rehabilitation, 256–257Michigan Alcoholism ScreeningTest, 126Moban. See Molindone (Moban)Molindone (Moban), dosing of,163tMoney management, assessmentof, 313Mood, quality of life and, 587Mood disorders, versusschizophrenia, 123Mood stabilizers, 186–189Morel, Benedict Augustine,theory of heredity, 11Mothersinfluenza/malnutrition in, 95so-called schizophrenic, 92Motivationfor illness self-management,270role in treatment, 406Motivation enhancement, for cooccurringSUDs, 466Motivational interviewing, forco-occurring SUDs, 466–467